James Kaye, MD, DrPH, a medical oncologist/hematologist and epidemiologist with over 20 years of experience, recently joined RTI Health Solutions (RTI-HS) as a Director of Epidemiology. He will be located in the Waltham, Massachusetts regional office.
Prior to RTI-HS, Dr. Kaye worked at Genetics Institute, Inc. (later Wyeth) where he directed clinical studies on several hematology/oncology products, two of which were approved for marketing, and participated in numerous FDA interactions, including IND and BLA submissions, Advisory Committee presentations, and label negotiations. Dr. Kaye subsequently completed doctoral training in epidemiology at the Harvard School of Public Health, where his research focused on pharmaceuticals and cancer risk.
Most recently he has been a senior epidemiologist at the Boston Collaborative Drug Surveillance Program and served on the faculty of the epidemiology department at Boston University School of Public Health. In addition to conducting his own epidemiology research on a broad array of drug safety issues, Dr. Kaye has chaired or participated in numerous independent data monitoring committees for advanced phase clinical trials of oncology drugs in development. He has authored approximately 50 articles in the peer-reviewed medical literature.
"I am delighted Jim has joined our team," said Susana Perez-Gutthann, MD, PhD, Vice President and Global Head of Epidemiology. "His expertise in oncology and pharmacoepidemiology will enhance the successes of RTI-HS and provide strong support to our clients in critical areas, especially pharmacoepidemiology and drug safety".
Dr. Kaye earned his medical degree from Stanford University and completed his internship and residency at the Beth Israel Hospital and his fellowship in medical oncology/hematology at the Dana Farber Cancer Institute. After completing his training, Dr. Kaye remained on the faculty in the Department of Medicine at Harvard Medical School while practicing medical oncology/hematology and coordinating the clinical research program at Harvard Community Health Plan.
"I am very pleased to join such a distinguished group of medical and epidemiologic researchers" said Dr Kaye. "RTI-HS has a reputation for excellence and producing high quality work products for its clients-a commitment that is substantiated by the level of scientific rigor it applies to all its research. More than ever, this commitment is necessary to thoroughly and effectively address the pressing issues that pharmaceutical clients face today."
About RTI Health Solutions
RTI Health Solutions provides scientifically rigorous research and consulting service in health economics, health outcomes, psychometrics, pricing and reimbursement, health preference assessment, epidemiology, pharmacovigilance, clinical development, and biostatistics to help biopharmaceutical companies successfully develop and gain market approval for their products.